drugset / Trial / NCT06045364

Effect of Glycopyrrolate on Nausea and Vomiting After ERCP Operation

NCT06045364

Phase 1/2 Completed 130 enrolled Jie Chen
RandomizedParallel-groupTriple-blindTreatment

Summary

This study aims to determine the role of Glycopyrrolate in preventing postoperative nausea and vomiting of ERCP.

Timeline

Start
2023-10-01
Primary completion
2024-07-20
Completion
2024-07-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Anisodamine Traditional medicine (herbal / TCM) 10 mg Intramuscular
Subject Glycopyrrolate Small molecule 0.2 mg Intravenous

Indications

No indication recorded.